Latest debt-to-equity ratio
enGene Therapeutics Debt-to-equity ratio
Direct answer
enGene Therapeutics's debt-to-equity ratio is 14.45%.
The verified market snapshot reports 14.45%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked October 20, 2026.
Get free enGene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Debt-to-equity ratio
- 14.45%